Stay updated on Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page
- Check3 days agoChange DetectedNew page footer revision tag shows Revision: v3.5.4, and the previous Revision: v3.5.3 was removed. This is a metadata update to the page version, with no change to the study details or user-facing functionality.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedClinicalTrials.gov page footer was updated from revision v3.5.2 to v3.5.3, indicating a change to the site/versioning rather than the underlying study record content.SummaryDifference0.1%

- Check32 days agoChange DetectedThe page revision was updated to v3.5.2, replacing the prior v3.5.0.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check75 days agoChange DetectedThe page footer revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check96 days agoChange DetectedMinor version update: Revision 3.4.2 replaces 3.4.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.